-
Mashup Score: 1Participants Discuss PI3K Inhibitors and Endocrine Resistance in Metastatic Breast Cancer - 14 hour(s) ago
During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor in patients with metastatic breast cancer.
Source: www.targetedonc.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Addressing Racial Disparities, Social Barriers to Breast Cancer Care - 17 hour(s) ago
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS, spoke with CancerNetwork® about potential initiatives to reduce racial disparities and other social barriers to receipt of guideline-concordant care for inflammatory breast cancer. #bcsm | @DrLolaFayanju https://t.co/viBirjdrdn
-
-
Mashup Score: 5Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer - 1 day(s) ago
This cohort study assesses whether having undergone a prior breast cancer screening is associated with earlier stage at breast cancer diagnosis and lower breast cancer–specific mortality.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Research suggests that prior mammography screening within five years of breast cancer diagnosis for seniors significantly reduces the risks of later-stage diagnosis and breast cancer-specific mortality #BCSM https://t.co/YxhJTJRFS7
-
-
Mashup Score: 4
Phase 2 data suggest a survival benefit with Bria-IMT and retifanlimab in heavily pretreated HR-positive metastatic breast cancer, outperforming historical controls.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
In a phase 2 trial, a potential survival benefit was seen with the combination of Bria-IMT and immune checkpoint inhibition in patients with heavily pretreated metastatic HR+ breast cancer. #bcsm https://t.co/ritIu5hprH
-
-
Mashup Score: 2
Additional results from the phase 2 IPAX-Linz trial will be reported at the 2025 Nuclear Medicine and Neurooncology Symposium.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
TLX101 demonstrated promising efficacy and a tolerable safety profile in the treatment of a small cohort of patients with recurrent high-grade glioma in the phase 2 IPAX-Linz trial. #bcsm https://t.co/EkRgDJY5J6 https://t.co/gTEjdDNbAq
-
-
Mashup Score: 9
Zongertinib showed responses across HER2-mutated tumor types, including in lung cancer, with a tolerable safety profile.
Source: www.onclive.comCategories: General Medicine NewsTweet-
The novel HER2-directed TKI zongertinib demonstrated preliminary efficacy and a manageable safety profile in patients with advanced or metastatic HER2-mutated solid tumors. #BCSM https://t.co/3mZtKSHcSL https://t.co/EhM2kXhQNe
-
-
Mashup Score: 4Vepdegestrant Improves PFS in ESR1-Mutated Breast Cancer - 3 day(s) ago
Vepdegestrant extended PFS vs fulvestrant in patients with ESR1m+, ER+/HER2– breast cancer who progressed on CDK 4/6 inhibitors and endocrine therapy.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
Treatment with vepdegestrant extended progression-free survival vs fulvestrant in patients with ESR1m+, ER+/HER2– breast cancer who progressed on CDK 4/6 inhibitors and endocrine therapy. #bcsm https://t.co/rry6k0hVFo
-
-
Mashup Score: 1
Fengting Yan, MD, PhD, discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
In this video, Fengting Yan, MD, PhD, (@FengtingYan) discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer. #bcsm https://t.co/9nQ0DtTq0q
-
-
Mashup Score: 1
Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer. #bcsm https://t.co/X3L9Tnx2AD
-
-
Mashup Score: 3Fellows Present Their Findings on the Breast Cancer Immune Microenvironment and Telehealth Delivery at National Fellows Forum - 5 day(s) ago
Tess O’Meara, MD, MHS, and Kelsey H. Natsuhara, MD, discuss their presentations from the OncLive National Fellows Forum at SABCS.
Source: www.onclive.comCategories: General Medicine NewsTweet-
During the OncLive National Fellows Forum® at SABCS, fellows from across the US, including Drs Tess O'Meara Kelsey H. Natsuhara, came together ahead of the meeting to share their research interests and network. @tess_omeara @KelseyNatsuhara #BCSM https://t.co/PMxr8LMvHU https://t.co/JizOoOvSdR
-
@VKaklamani and participants discussed their experiences using a PI3K/AKT inhibitor in patients with metastatic breast cancer. #bcsm | @UTHealthSAMDA https://t.co/oXT8Hs33sn